Physician profile
Malini Venkatram
NPI 1467639948
$1,973.92
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $764 · 2020: $233 · 2021: $551 · 2022: $426.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $462.37 | 2019-2022 | |
| Janssen Biotech, INC. | $460.26 | 2019-2022 | |
| Horizon Therapeutics Plc | $288.30 | 2019-2022 | |
| Abbvie INC. | $249.65 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $176.71 | 2019-2020 | |
| Glaxosmithkline, LLC. | $114.74 | 2019-2022 | |
| Ucb, INC. | $80.61 | 2019-2022 | |
| Amgen INC. | $48.38 | 2019-2020 | |
| Genentech USA, INC. | $40.82 | 2019 | |
| Aurinia Pharma U.S., INC. | $19.69 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $16.39 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.00 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malini Venkatram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.